Other languages Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
22.62 ^USD	-3.33%		-0.44%	-24.52%

May. 16	Transcript : Rocket Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM
May. 10	UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy	May. 10
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06
Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	Apr. 16
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	Apr. 11
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102	Apr. 02
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	Apr. 02
Rocket Pharmaceuticals, Inc. Announces Executive Appointments	Mar. 26
Rocket Pharmaceuticals Q4 Loss Narrows	Feb. 26
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 25
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline	Feb. 13
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)	Feb. 13
Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director	Dec. 12
Rocket Pharmaceuticals Insider Sold Shares Worth $450,646, According to a Recent SEC Filing	Nov. 17
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 05
Rocket Pharmaceuticals Insider Sold Shares Worth $315,744, According to a Recent SEC Filing	23-10-03
Rocket Pharmaceuticals' Biologics License Application for Gene Therapy Accepted by US FDA for Priority Review	23-10-02
Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)	23-10-02
RTW Biotech's Rocket Pharmaceuticals makes Danon progress	23-09-14
MÄRKTE USA/Kaum verändert - Nach Preisdaten bleiben Zweifel	23-09-13
Wall Street verdeeld gesloten	23-09-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Other languages

Filters